Profil bibliographique

Larry Rubinstein

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

463Publications signalées

68144Citations signalées

2Affiliations récentes

Les institutions déclarées

National Cancer Institute National Cancer Institute

Les domaines associés

Lung Cancer Treatments and MutationsStatistical Methods in Clinical TrialsCancer Genomics and DiagnosticsPARP inhibition in cancer therapyColorectal Cancer Treatments and Studies

Les publications récentes

Accès ouvert 2026 article OpenAlex

ERK1/2 Inhibitor Ulixertinib in Pancancer Patients with BRAF Fusions or Non-V600E/K Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1L

Vivek Subbiah, Fengmin Zhao, Ragini R. Kudchadkar, Ryan J. Sullivan et autres

us, my (code pays fourni par la source)

0 citations Clinical Cancer Research

Accès ouvert 2026 article OpenAlex

Multicenter Phase I Study of Triapine in Combination with [177Lu]Lutetium-Dotatate in Patients with Well-Differentiated Neuroendocrine Tumors (ETCTN 10388)

Aman Chauhan, Heidi L. Weiss, Charles Kunos, Rani Jayswal et autres

us, ph (code pays fourni par la source)

0 citations Clinical Cancer Research

Accès ouvert 2026 article OpenAlex

Phase II Study of Adavosertib in Patients With Tumors Containing BRCA1 and BRCA2 Mutations: Results From the NCI-MATCH ECOG-ACRIN Cancer Research Group (EAY131) Subprotocol Z1I

Shivaani Kummar, Zihe Song, Kim A. Reiss, James M. Ford et autres

us, my (code pays fourni par la source)

0 citations JCO Precision Oncology

Accès ouvert 2026 article OpenAlex

Larotrectinib in Patients With Tumors With NTRK Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol EAY131-Z1E

Neal S. Akhave, Zihe Song, David Hong, Robert J. Gray et autres

us (code pays fourni par la source)

2 citations JCO Precision Oncology

Accès ouvert 2026 article OpenAlex

Crizotinib in Patients with Tumors with MET Amplification or Exon 14 Deletion: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols C1 and C2

N. Coleman, Zihan Wei, A. John Iafrate, James A. Zwiebel et autres

us, ie, my (code pays fourni par la source)

1 citation Clinical Cancer Research

Accès ouvert 2025 article OpenAlex

A phase 1 study of orally administered 5-fluoro-2’-deoxycytidine with tetrahydrouridine in patients with refractory solid tumors

Alice P. Chen, Shivaani Kummar, Larry Rubinstein, Jennifer Zlott et autres

my, us (code pays fourni par la source)

1 citation Cancer Chemotherapy and Pharmacology

Accès ouvert 2025 supplementary-materials OpenAlex

Supplementary Figure 1 from Ipatasertib in Patients with Tumors with AKT Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1K

Carolyn K. McCourt, Zihan Wei, Kevin Kalinsky, Robert J. Gray et autres

0 citations

Accès ouvert 2025 supplementary-materials OpenAlex

Supplementary Figure 2 from Ipatasertib in Patients with Tumors with AKT Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1K

Carolyn K. McCourt, Zihan Wei, Kevin Kalinsky, Robert J. Gray et autres

0 citations

Accès ouvert 2025 other OpenAlex

Data from Ipatasertib in Patients with Tumors with AKT Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1K

Carolyn K. McCourt, Zihan Wei, Kevin Kalinsky, Robert J. Gray et autres

0 citations

Accès ouvert 2025 supplementary-materials OpenAlex

Supplementary Table 2 from Ipatasertib in Patients with Tumors with AKT Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1K

Carolyn K. McCourt, Zihan Wei, Kevin Kalinsky, Robert J. Gray et autres

0 citations

Accès ouvert 2025 supplementary-materials OpenAlex

Supplementary Data 1 from Ipatasertib in Patients with Tumors with AKT Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1K

Carolyn K. McCourt, Zihan Wei, Kevin Kalinsky, Robert J. Gray et autres

us (code pays fourni par la source)

0 citations

Accès ouvert 2025 supplementary-materials OpenAlex

Supplementary Table 3 from Ipatasertib in Patients with Tumors with AKT Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1K

Carolyn K. McCourt, Zihan Wei, Kevin Kalinsky, Robert J. Gray et autres

0 citations

Profil ORCID Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.